P3 Health Partners (PIII) Expected to Announce Quarterly Earnings on Thursday

P3 Health Partners (NASDAQ:PIII) will likely be issuing its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($4.85) per share and revenue of $391.45 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:30 PM ET.

P3 Health Partners (NASDAQ:PIII) last released its earnings results on Thursday, March 26th. The company reported ($23.02) earnings per share for the quarter, missing the consensus estimate of ($8.06) by ($14.96). P3 Health Partners had a negative net margin of 10.14% and a negative return on equity of 302.33%. The firm had revenue of $384.81 million during the quarter, compared to the consensus estimate of $357.65 million.

P3 Health Partners Trading Up 6.5%

NASDAQ PIII opened at $3.78 on Tuesday. The firm’s fifty day moving average price is $2.78 and its two-hundred day moving average price is $3.90. P3 Health Partners has a 1 year low of $1.52 and a 1 year high of $11.30. The firm has a market capitalization of $27.25 million, a P/E ratio of -0.08 and a beta of 0.48.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of P3 Health Partners in a research note on Tuesday, April 21st. TD Cowen reduced their price target on P3 Health Partners from $8.00 to $3.00 and set a “hold” rating for the company in a report on Thursday, April 2nd. Finally, Lake Street Capital reduced their price target on P3 Health Partners from $12.50 to $4.00 and set a “buy” rating for the company in a report on Friday, March 27th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $3.50.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.